For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150 ...

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type ...

Beacon Journal sports writer George M. Thomas shares his story of renal disease and subsequent kidney transplant.

Living kidney donors with discordant kidney function measures had lower eGFR after donation and a higher risk for eGFR counts below 45 mL/min/1.73 m2, researchers found. “Living donor kidney ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

In a remarkable display of market confidence, VATE stock has surged to a 52-week high, with shares trading at an impressive $13.31, representing a dramatic 309% increase from its 52-week low of $3.25.